What Happened

Moonwalk Biosciences, a US biotech developing adipose-targeted RNAi therapeutics for obesity and cardiometabolic diseases, announced a $70M oversubscribed Series B financing. The round was co-led by Alpha Wave Ventures and YK Bioventures, with participation from Eli Lilly and Company, Gaorong Ventures, and existing investors ARCH Venture Partners, Khosla Ventures, and Future Ventures. The company will use the proceeds to advance its lead candidate MW101 into human clinical trials by late 2027 after completing IND-enabling studies, expand its siRNA pipeline, and further develop its proprietary discovery platform.

Who Is Affected

Moonwalk itself will scale its clinical and R&D operations, with a new SVP of clinical development (Stephen Djedjos) onboard to lead trial execution. This creates immediate engagement opportunities for CROs, clinical trial software providers, preclinical research vendors, and biotech analytics firms. Investors and existing partners like Eli Lilly will monitor progress, while competitors in the obesity space face a new RNAi-based challenger.

Market Impact

Key implications for the RNAi and obesity therapy market:

• Moonwalk's adipose-targeted approach offers a novel mechanism distinct from GLP-1 agonists, potentially capturing a segment of the obesity market focused on muscle preservation and durable dosing.
• Eli Lilly's strategic investment signals confidence in RNAi as a viable obesity modality and may accelerate partner discussions.
• The $70M round validates RNAi delivery to adipose tissue, likely spurring interest from other biotechs and investors in similar platform technologies.
• Preclinical data showing weight and fat mass reduction without appetite suppression suggests a differentiator that could reshape treatment paradigms if replicated in humans.

What to Watch

Track Moonwalk's IND submission timeline and selection of CRO partners for the MW101 Phase 1 trial. Monitor for additional pipeline expansion disclosures and potential licensing deals around its adipose-targeting chemistry. The company's hiring trajectory—especially in clinical development and regulatory affairs—will indicate the pace of operational scaling. Early clinical data on safety and efficacy will be critical for the broader RNAi-obesity thesis.

Related coverage

• Split Pay raises $125M across Series A and B for paycheck-timing fintech
• FDA approves Inluriyo (imlunestrant) + Verzenio combination for ER+ HER2- ESR1-mutated metastatic breast cancer
• Lilly to acquire Merida Biosciences for up to $2.875B
• BrainChild Bio raises $116M Series A for CAR-T therapies